Published in Vaccine Weekly, May 10th, 2006
Study 1: Vaccination with altered peptide ligand-loaded dendritic cells induced cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors.
According to recent research published in the journal Cancer Immunology Immunotherapy, "Dendritic cells (DCs) are characterized by their extraordinary capacity to induce T-cell responses, providing the opportunity of DC-based cancer vaccination protocols. In the present study, we conducted a phase I/II clinical trial to determine the capability of DCs differentiated from immunomagnetically...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-05-10)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.